In both TCGA PanCancer and MSKCC cohorts, ARFGEF2 downregulations increased the risk of PC relapse (Figure 7) and this biomarker value is independent of age at diagnosis, tumor stage, WHO PC grade, and surgical margin status. Here, ARFGEF2 is linked to pachyonychia congenita.